

1 3. Defendants violate the Act, 21 U.S.C. § 331(k), by causing articles of food,
2 within the meaning of 21 U.S.C. § 321(f), to become adulterated, within the meaning of 21
3 U.S.C. § 342(a)(4), while such articles are held for sale after shipment of one or more of their
4 components in interstate commerce. The articles of food are adulterated within the meaning of
5 21 U.S.C. § 342(a)(4) in that they have been prepared, packed, or held under insanitary
6 conditions whereby they may have become contaminated with filth or whereby they may have
7 been rendered injurious to health.

8 4. Upon entry of this Decree, Defendants represent to the Court that Defendants are
9 not directly or indirectly engaged in manufacturing, processing, packing, labeling, holding,
10 and/or distributing any articles of food from the facility at 2630 5th Street, Unit 92, Sacramento,
11 California 95818, or from any other location. Defendants also represent to the Court that Henk
12 Wong Fresh Produce has ceased all operations and production, and has completed the
13 dissolution process. Defendants have neither transferred nor sold any business assets or
14 equipment, nor assigned any assets to third parties. If any Defendant later intends to resume
15 operations at 2630 5th Street, Unit 92, Sacramento, California 95818, or any other location,
16 Defendants must first notify the United States Food and Drug Administration ("FDA") in
17 writing at least ninety (90) calendar days in advance of resuming operations and must comply
18 with paragraphs 5(A) through (M) of this Decree. This notice shall identify the type(s) of food
19 Defendants intend to receive, prepare, process, pack, label, hold, and/or distribute, and the
20 facility in which Defendants intend to resume operations. Defendants shall not resume
21 operations until FDA has first inspected Defendants' facility and operations pursuant to
22 paragraph 5(L), Defendants have paid the costs of such inspection(s) pursuant to paragraph
23 5(M), and Defendants have received written notice from FDA, as required by paragraph 5(N),
24 and then shall resume such food operations only to the extent authorized in FDA's written
25 notice.

26 5. Defendants and each and all of their directors, officers, agents, representatives,
27 employees, attorneys, successors, assigns, and any and all persons or entities in active concert or

1 participation with any of them (including individuals, partnerships, corporations, subsidiaries,
2 and affiliates), who receive actual notice of this Decree (collectively, "Associated Persons"), are
3 hereby permanently restrained and enjoined, under 21 U.S.C. § 332(a) and the equitable
4 authority of this Court, from directly or indirectly receiving, preparing, processing,
5 manufacturing, labeling, packing, holding, or distributing any food from or at the facility at
6 2630 5th Street, Unit 92, Sacramento, California 95818 and any other or new locations at which
7 Defendants now, or in the future, directly or indirectly receive, prepare, process, manufacture,
8 label, pack, hold, and/or distribute food (collectively, "Defendants' facility"), unless and until
9 all of the following occur:

10 A. Defendants retain, at their expense, an independent person or persons (the
11 "Sanitation Expert") who is without any personal or financial ties (other than the retention
12 agreement) to Defendants or their families, and who, by reason of background, education,
13 training, or experience, is qualified to develop and implement a written sanitation control and
14 food safety plan ("Sanitation Control and Food Safety Plan"), covering Defendants' tofu and
15 sprout manufacturing processes, cleaning and sanitizing operations, pest control, employee
16 health and hygiene precautions, and plant construction and maintenance (including the plant's
17 buildings and sanitation-related systems, equipment, and utensils contained therein) that will
18 protect food, food contact surfaces, and food-packaging materials from contamination from any
19 source including, but not limited to, chemicals, toxins, microorganisms, filth, and vermin;

20 B. Defendants notify FDA in writing of the name and qualifications of the
21 Sanitation Expert as soon as they retain such expert;

22 C. Defendants' Sanitation Expert, after review of all FDA observations from
23 July 2003 to present, develops an effective written Sanitation Control and Food Safety Plan (in
24 English and Chinese) which shall, at a minimum:

25 i. Establish adequate methods, facilities, and controls for receiving,
26 processing, manufacturing, preparing, packing, holding, and/or distributing articles of food to
27 minimize the risk of contamination of food, food contact surfaces, and food packaging

1 materials, and to ensure that foods are not adulterated within the meaning of 21 U.S.C.
2 § 342(a)(4). Such methods, facilities, and controls shall include, but shall not be limited to,
3 thoroughly cleaning, sanitizing, renovating, and rendering Defendants' facility and all
4 equipment therein suitable for use in receiving, processing, manufacturing, preparing, packing,
5 holding, and distributing articles of food to prevent the articles of food from becoming
6 adulterated; instituting standard sanitation operating procedures ("SSOPs"); instituting a
7 cleaning and sanitizing schedule; and instituting monitoring and record-keeping procedures to
8 ensure that Defendants' facility and equipment therein are continuously maintained in a sanitary
9 condition;

10 ii. Ensure that Defendants adhere to the current good manufacturing
11 practice ("cGMP") requirements, see 21 C.F.R. Part 110;

12 iii. Require that the adequacy of cleaning and sanitizing be routinely
13 verified through targeted environmental swabbing and appropriate microbial testing;

14 iv. Require that seeds and beans used for sprouting are conditioned,
15 stored, and transported in a manner that minimizes the likelihood that they will be contaminated
16 with pathogens: that seeds are stored in closed or covered containers in a clean, dry area
17 dedicated to seed and bean storage; and that containers are positioned off the floor and away
18 from walls to reduce the possibility of contamination by rodents or other pests, and to facilitate
19 regular monitoring for pest problems;

20 v. Require that seeds and beans used for sprouting be treated with
21 one or more scientifically valid treatments to reduce pathogens in seeds or sprouts immediately
22 prior to sprouting, and that Defendants monitor and control the parameters of the scientifically
23 valid treatment(s);

24 vi. Require Defendants to conduct microbiological testing of spent
25 irrigation water from each production lot to ensure that contaminated product is not distributed.
26 Defendants must obtain the test results before shipping product and shall not ship any product
27 from a production lot where contamination is found;

1 vii. Establish written procedures for remedial action should any
2 pathogenic organism be detected;

3 viii. Establish a written employee training program (in English and
4 Chinese) that includes, at a minimum, instruction in sanitation control requirements for food-
5 handling and manufacturing, and documentation that each employee has received such training.
6 Defendants' Sanitation Expert shall test to confirm that each employee fully understands the
7 substance of the employee training program;

8 D. FDA approves, in writing, the Sanitation Control and Food Safety Plan;

9 E. Defendants make written copies of the Sanitation Control and Food
10 Safety Plan available and accessible to all of their employees;

11 F. Defendants assign continuing responsibility for implementing and
12 monitoring the Sanitation Control and Food Safety Plan to a person(s), who, by reasons of
13 background, education, training or experience, is competent to maintain Defendants' facility in
14 a sanitary condition, coordinate with the laboratory, and implement any necessary remedial
15 action(s), and provide such person with the authority to achieve the necessary corrections;

16 G. Defendants complete a training program developed per paragraph
17 5(C)(viii), that includes, at a minimum, instructions in sanitation control requirements for food
18 handling and manufacturing, and Defendants document that each employee has received such
19 training;

20 H. Defendants develop and implement a system to facilitate traceback and
21 recalls in the event of a violation or the potential for food-borne illness, and Defendants test
22 their system to ensure that it will be adequate;

23 I. The Sanitation Expert conducts a comprehensive inspection of
24 Defendants' facility, including the buildings, sanitation-related systems, equipment, utensils,
25 articles of food, and relevant records contained therein, to determine whether Defendants have:
26 adequately established and implemented the Sanitation Control and Food Safety Plan;
27 adequately addressed FDA investigators' inspectional observations listed on each Form FDA

28

1 483 issued to Defendants since July 2003 and any other violations noted by any state authority;
2 and are operating in compliance with this Decree, the Act, and its implementing regulations.

3 The Sanitation Expert should submit all findings to Defendants and FDA concurrently within
4 ten (10) calendar days of completion of the inspection;

5 J. The Sanitation Expert certifies in writing to FDA that Defendants:

6 i. Have a copy of the FDA approved Sanitation Control and Food
7 Safety Plan and have adequately established and implemented it;

8 ii. Have adequately addressed the Form FDA 483 observations; and

9 iii. Have complied with the cGMP requirements for food, sec 21

10 C.F.R. Part 110;

11 K. Within thirty (30) calendar days after entry of this Decree, Defendants
12 destroy, under FDA's supervision, and according to a destruction plan submitted in writing by
13 Defendants and approved by FDA in writing prior to implementation, all raw ingredients and
14 in-process and finished articles of food currently in their custody, control, or possession as of
15 the date this Decree is signed by the parties;

16 L. FDA, as it deems necessary to evaluate Defendants' compliance with the
17 terms of this Decree, the Act, and its implementing regulations, conducts inspections of
18 Defendants' facility, including the buildings, sanitation-related systems, equipment, utensils, all
19 articles of food, and relevant records contained therein;

20 M. Defendants have paid all costs of inspection(s), analysis, review,
21 investigation(s), examination, and supervision for FDA's oversight with respect to paragraphs
22 5(A) through (L), at the rates set forth in paragraph 10 below; and

23 N. FDA notifies Defendants in writing that Defendants appear to be in
24 compliance with the requirements set forth in paragraphs 5(A) through (M) of this Decree, the
25 Act, and its implementing regulations.

26 6. Upon resuming operations after completing the requirements of paragraph 5,
27 Defendants shall continuously and effectively implement on an ongoing basis, the Sanitation

1 Control and Food Safety Plan developed pursuant to paragraph 5(C). In the event that
2 Defendants or their Sanitation Expert determine that the sanitation control program needs to be
3 revised, Defendants shall provide suggested changes to FDA in writing at least twenty (20)
4 calendar days prior to their planned implementation, and shall not implement their suggested
5 changes until FDA approves those changes in writing.

6 7. Notwithstanding paragraphs 4–6 of this Decree, Defendant Kin Ly may
7 participate in receiving, preparing, processing, manufacturing, labeling, packing, holding, or
8 distributing food for any corporation, partnership, firm, company, business, entity, and/or
9 persons (“the Employer”), other than the remaining Defendants or any entity controlled, directly
10 or indirectly, by any of the remaining Defendants, as long as the following conditions are met:

11 A. Defendant Kin Ly may only be employed or otherwise engaged with the
12 Employer in receiving, preparing, processing, manufacturing, labeling, packing, holding, or
13 distributing any type of food, in a non-management capacity (e.g., as a general laborer or
14 production employee).

15 B. Defendant Kin Ly may not be employed by or otherwise engaged in
16 receiving, preparing, processing, manufacturing, labeling, packing, holding, or distributing any
17 type of food with any of the remaining Defendants or any entity controlled, directly or
18 indirectly, by any of the remaining Defendants.

19 C. Before becoming employed or otherwise engaged in receiving, preparing,
20 processing, manufacturing, labeling, packing, holding, or distributing any type of food,
21 Defendant Kin Ly must notify and provide a copy of this Decree to the Employer.

22 D. Defendant Kin Ly shall provide FDA an affidavit at least ten (10)
23 business days prior to becoming employed by or otherwise engaged with the Employer, and
24 such affidavit shall include the name and address of the Employer and identify the names,
25 addresses, and positions of all persons at the Employer who Defendant Kin Ly notified and
26 provided a copy of this Decree.

27
28

1 E. In addition to the affidavit required in paragraph 7(D), Defendant Kin Ly
2 shall also provide to FDA an affidavit with a detailed description of his employment duties
3 within ten (10) business day of beginning his employment. If Defendant Kin Ly's employment
4 duties change during the course of his employment with the Employer, Defendant Kin Ly shall
5 provide to FDA an affidavit detailing his new employment duties within ten (10) business days
6 of assuming his new duties.

7 8. Defendants and each and all of the Associated Persons who receive actual notice
8 of this Decree, are permanently restrained and enjoined under the provisions of 21 U.S.C.
9 § 332(a) from, directly or indirectly, doing or causing any act that:

10 A. Violates 21 U.S.C. § 331(k), by causing articles of food within the
11 meaning of 21 U.S.C. § 321(f) to become adulterated within the meaning of 21 U.S.C.
12 § 342(a)(4) while such articles are held for sale after shipment of one or more of their
13 components in interstate commerce; and/or

14 B. Results in the failure to implement and continuously maintain the
15 requirements of this Decree.

16 9. Representatives of FDA shall be permitted, without prior notice and as and when
17 FDA deems necessary, to inspect Defendants' facility and operations, and take any other
18 measures necessary to monitor and ensure continuing compliance with the terms of this Decree,
19 the Act, and its implementing regulations. During the inspections, FDA shall be permitted to
20 have immediate access to buildings, equipment, raw ingredients, finished and unfinished
21 materials and products, containers, labeling, and packaging material therein; to take
22 photographs and make video recordings; to take samples of Defendants' raw ingredients,
23 finished and unfinished materials and products, containers, labeling, packaging material, and
24 other material; and to examine and copy all records related to receiving, preparing, processing,
25 manufacturing, labeling, packing, holding, and distributing any and all of Defendants' products.
26 The inspections shall be permitted upon presentation of a copy of this Decree and appropriate
27

1 credentials. The inspection authority granted by this Decree is separate from, and in addition to,
2 the authority to make inspections under the Act, 21 U.S.C. § 374.

3 10. Defendants shall pay all costs of FDA's supervision, inspections, investigations,
4 analyses, examinations, sampling, testing, reviews, document preparation, travel, and
5 subsistence expenses that FDA deems necessary to evaluate Defendants' compliance with any
6 part of this Decree, at the standard rates prevailing at the time costs are incurred, and
7 Defendants shall make payment in full to FDA within twenty (20) business days of receiving
8 written notification from FDA of the costs. As of the date that this Decree is signed by the
9 parties, these rates are: \$89.35 per hour and fraction thereof per representative for inspection or
10 investigative work; \$107.09 per hour or fraction thereof per representative for analytical or
11 review work; \$0.575 per mile for travel by automobile; government rate or the equivalent for
12 travel by air or other means; and the published government per diem rate or the equivalent for
13 the areas in which the inspections are performed per representative and per day for subsistence
14 expenses. In the event that the standard rates applicable to FDA supervision of court-ordered
15 compliance are modified, these rates shall be increased or decreased without further order of the
16 Court.

17 11. Within ten (10) business days after the date of Defendants' notice to FDA as
18 described in paragraph 4, Defendants shall post a copy of this Decree (in English and Chinese)
19 prominently in an employee common area at Defendants' facility and shall ensure that this
20 Decree remains posted for as long as this Decree remains in effect. Within fifteen (15) business
21 days after the date of Defendants' notice to FDA as described in paragraph 4, Defendants shall
22 provide to FDA an affidavit, from a person with personal knowledge of the facts stated therein,
23 stating the fact and manner of Defendants' compliance with this paragraph.

24 12. Within ten (10) business days after the date of Defendants' notice to FDA as
25 described in paragraph 4, Defendants shall hold a general meeting or series of smaller meetings
26 for all employees, at which they shall describe the terms and obligations of this Decree. Within
27 fifteen (15) business days after the date of Defendants' notice to FDA as described in paragraph

1 4, Defendants shall provide to FDA an affidavit, from a person with personal knowledge of the
2 facts stated therein, stating the fact and manner of Defendants' compliance with this paragraph,
3 and a copy of the agenda, list of attendees, and meeting minutes from the meeting(s) held
4 pursuant to this paragraph.

5 13. Within ten (10) business days after entry of this Decree, Defendants shall
6 provide a copy of this Decree, by personal service or certified mail (restricted delivery, return
7 receipt requested), to each and all of the Associated Persons. Defendants shall provide to FDA
8 within twenty (20) business days after the date of the entry of this Decree an affidavit, from a
9 person with personal knowledge of the facts stated therein, stating the fact and manner of
10 compliance with this paragraph, identifying the names, addresses, and positions of all persons
11 so notified, and attaching a copy of the executed certified mail return receipts.

12 14. In the event that any Defendant becomes associated with any additional
13 Associated Person(s) at any time after entry of this Decree, Defendants shall immediately
14 provide a copy of this Decree, by personal service or certified mail (restricted delivery, return
15 receipt requested), to such Associated Person(s). Within ten (10) business days of each instance
16 that any Defendant becomes associated with any additional Associated Person, Defendants shall
17 provide to FDA an affidavit, from a person with personal knowledge of the facts stated therein,
18 stating the fact and manner of Defendants' compliance with this paragraph, identifying the
19 names, addresses, and positions of all persons who received a copy of this Decree pursuant to
20 this paragraph, and attaching a copy of the executed certified mail return receipts. Within ten
21 (10) business days of receiving a request from FDA for any information or documentation that
22 FDA deems necessary to evaluate Defendants' compliance with this paragraph, Defendants
23 shall provide such information or documentation to FDA.

24 15. Defendants shall notify FDA in writing at least fifteen (15) calendar days before
25 any change in ownership, name, or character of their business, including incorporation,
26 reorganization, relocation, dissolution, assignment, or lease or sale of the business or any assets
27 of the business, such as buildings, equipment, or inventory, that may affect compliance with the

1 obligations arising from this Decree. Defendants shall provide any prospective successor or
2 assign with a copy of this Decree at least ten (10) calendar days before the assignment or change
3 in business, and shall provide to FDA an affidavit, from a person with personal knowledge of
4 the facts stated therein, stating the fact and manner of Defendants' compliance with this
5 paragraph within ten (10) calendar days of providing a copy of this Decree to a prospective
6 successor or assign.

7 16. If, at any time after entry of this Decree, FDA determines, based on the results of
8 an inspection, sample, analyses, or other information, that Defendants have failed to comply
9 with any provision of this Decree, have violated the Act or its implementing regulations, or that
10 additional corrective actions are necessary to achieve compliance with this Decree, the Act or its
11 implementing regulations, FDA may, as and when it deems necessary, notify Defendants in
12 writing and order Defendants to take appropriate action, including, but not limited to, ordering
13 Defendants to immediately take one or more of the following actions:

14 A. Cease receiving, preparing, processing, manufacturing, labeling, packing,
15 holding, and/or distributing any articles of food;

16 B. Recall all articles of food that have been distributed and/or are under the
17 custody and control of Defendants' agents, distributors, customers, or consumers;

18 C. Submit samples of raw ingredients, and in-process and finished articles of
19 food to a qualified laboratory to determine whether they are contaminated with chemicals,
20 toxins, microorganisms, or filth; and/or

21 D. Take any other corrective actions that FDA deems necessary to bring
22 Defendants into compliance with this Decree, the Act, and its implementing regulations. The
23 provisions of this paragraph shall be separate and apart from, and in addition to, all other
24 remedies available to FDA. Defendants shall pay all costs of recalls and other corrective
25 actions, including the costs of FDA's supervision, inspections, investigations, analyses,
26 examinations, sampling, testing, reviews, document preparation, travel, and subsistence
27
28

1 expenses to implement and monitor recalls and other actions, at the rates specified in paragraph
2 10 of this Decree.

3 17. Upon receipt of any order issued by FDA pursuant to paragraph 16, Defendants
4 shall immediately and fully comply with the terms of the order. Any cessation of operations or
5 other action as described in paragraph 16 shall be implemented immediately upon notice from
6 FDA and shall continue until Defendants receive written notification from FDA that Defendants
7 appear to be in compliance with this Decree, the Act, and its implementing regulations. After a
8 cessation of operations, and while determining whether Defendants are in compliance with this
9 Decree, the Act, and its implementing regulations, FDA may require Defendants to re-institute
10 or re-implement any of the requirements of this Decree.

11 18. If any Defendant fails to comply with the provisions of this Decree, the Act,
12 and/or its implementing regulations, then Defendants shall pay to the United States of America
13 liquidated damages in the sum of five thousand dollars (\$5,000) for each day that Defendants
14 fail to comply with this Decree, an additional sum of five hundred dollars (\$500) in liquidated
15 damages per day for each violation of this Decree, the Act, and/or its implementing regulations,
16 and an additional sum equal to twice the retail value of each shipment of adulterated food.
17 Defendants understand and agree that the liquidated damages specified in this paragraph are not
18 punitive in nature and their imposition does not in any way limit the ability of the United States
19 to seek, and the Court to impose, additional civil or criminal penalties based on the conduct that
20 may also be the basis for payment of the liquidated damages.

21 19. If any Defendant violates this Decree and is found in contempt thereof,
22 Defendants shall, in addition to other remedies, reimburse Plaintiff for its attorneys' fees, travel
23 expenses incurred by attorneys and witnesses, expert witness fees, administrative and court
24 costs, investigation and analytical expenses incurred in bringing the contempt action, and any
25 other costs or fees related to the contempt proceedings.

26 20. All decisions specified in this Decree shall be vested in the discretion of FDA.
27 FDA's decisions shall be final and, if challenged, shall be reviewed by the Court under the

1 arbitrary and capricious standard set forth in 5 U.S.C. § 706(2)(A). Review by the Court of any
2 FDA decision rendered pursuant to this Decree shall be based exclusively on the written record
3 before FDA at the time the decision was made. No discovery shall be taken by either party.

4 21. All notifications, correspondence, and communications to FDA required by the
5 terms of this Decree shall be prominently marked "Decree Correspondence" and addressed to
6 District Director, San Francisco District Office, United States Food and Drug Administration,
7 1431 Harbor Bay Parkway, Alameda, California 94502, and shall reference this civil action by
8 case name and civil action number.

9 22. This Court retains jurisdiction of this action and the parties hereto for the
10 purpose of enforcing and modifying this Decree and for the purpose of granting such additional
11 relief as may be necessary and appropriate.

12 SO ORDERED, this 3rd day of August, 2015.

13 
14 _____
15 UNITED STATES DISTRICT JUDGE

15 Entry consented to:


~~Spencer S. ...~~ Carolyn K. Delaney
~~For Plaintiff~~ U.S. Magistrate Judge
For Plaintiff


16 For Defendants

17 Dated this 30th day of June, 2015

18 HENH WONG FRESH PRODUCE,
19 a sole proprietorship

Respectfully submitted.

20 
21 DAVID C. LY,
22 in his individual capacity and as sole
23 proprietor of Henh Wong Fresh Produce

24 MICHAEL S. BLUME
25 Director
26 
27 Melanie Singh
28 Counsel
29 Consumer Protection Branch
30 United States Department of Justice
31 Liberty Square Building - Room
32 6400 South
33 450 Fifth St., NW
34 Washington, DC 20001
35 Telephone: (202) 616-9928
36 Fax: (202) 514-8742

24 
25 THANH "DANNY" C. LY.
26 in his individual capacity

27 
28 KIN S. LY, in his individual capacity

Of Counsel:

K. J. Petsas

24/JUNE/15

1 K. J. Petsas, Esq.
2 Attorney for Defendants
3 1475 Huntington Ave, Suite 205
4 South San Francisco, CA 94080
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

WILLIAM B. SCHULTZ
General Counsel

ELIZABETH H. DICKINSON
Chief Counsel
Food and Drug Division

PERHAM GORJI
Deputy Chief Counsel for
Litigation

LAURA J. AKOWUAH
Associate Chief Counsel
U.S. Department of Health and
Human Services
Office of the General Counsel
10903 New Hampshire Avenue
Silver Spring, MD 20994

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California }
County of SACRAMENTO }

On 6/22/15 before me, JOSEPH MAITA - NOTARY PUBLIC
(here insert name and title of the officer)

personally appeared DAVID C LY, THANNH C. LY & KIN S. LY

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature *Joseph Maita*

(Seal)

